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Abstract: Radiation therapy often plays a critical role in the treatment
of thymic malignancies. However, because of the location of these
tumors, historically patients have been at a significant risk for radiation-
related toxicity such as pericardial effusions, radiation pneumonitis,
long-term pulmonary fibrosis, and occasional long-term esophageal
stricture, particularly for unresectable thymoma. Recent advancements
in technology have provided the treating radiation oncologist with the
ability to more accurately target the region at risk while sparing normal
structures. In this review, we provide an overview of key advances in
radiation techniques for thymoma over the past two decades. These
techniques include 3D conformal therapy, intensity-modulated radia-
tion therapy, 4D treatment planning, adaptive radiation therapy, and
proton therapy. Each advancement has brought with it unique advan-
tages in maintaining long-term disease control while improving quality
of life in this manageable disease.
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Radiation treatment for thymoma has the potential to carrywith it significant toxicity. In addition to the acute damage to
the surrounding critical structures such as the heart, lung, and
esophagus, the favorable long-term survival in this disease also
necessitates that prioritization is given toward preventing
chronic adverse events. This issue is further complicated by the
fact that there have been publications from several institutions,
including our own, that have implemented induction chemother-
apy to reduce the rate of pleural recurrences.1 However, this
regimen includes doxorubicin, which is also cardiotoxic. Studies
on Hodgkin lymphoma have demonstrated long-term cardiac
morbidity with mediastinal radiation and have concluded that
this risk is compounded greatly with the addition of doxorubi-
cin.2 Furthermore, our institution has previously analyzed data
from 101 patients with inoperable esophageal cancer treated
with definitive chemoradiation and found that a number of
dose-volume histogram parameters to the pericardium and heart
were associated with a risk of pericardial effusion.3 Another
study demonstrated that with lung cancer, chemotherapy and
radiation to centrally located lung tumors cause defects in
cardiac perfusion anteriorly, corresponding to those regions
that have received higher levels of radiation.4 Similar con-
clusions about long-term toxicity have been made with re-
spect to pulmonary side effects such as late radiation fibro-
sis.5 It is in this context that the advancement of radiation
techniques could have a large impact on reducing serious
morbidity, and that this benefit will continue to be witnessed
for many years to come.
Radiation therapy has made significant technological
strides over the past two decades. The first of these advance-
ments came with the introduction of 3D conformal therapy,
which represented a major shift from conventional, “2D”
techniques. With this method, physicians were able to select
optimal beam angles that could shape the treatment field
while minimizing dose to critical normal structures. Then, in
the past decade, the field of radiation oncology has witnessed
an explosion in intensity-modulated radiation therapy
(IMRT) that uses the revolutionary technique of “inverse
planning” to optimize doses to the tumor and normal tissue
using planning software that delivers a nonuniform radiation
dose within the radiation field, further improving dosimetric
conformality and thus the therapeutic ratio with radiation
delivery. Finally, even more recently there has been a nation-
wide increase in the application of proton therapy for multiple
disease sites. Proton therapy has a theoretical dosimetric
advantage over photon techniques such as IMRT through the
production of a “Bragg Peak,” which provides a sharp in-
crease in dose at a given depth in tissue that can be modulated
by the treating physician. Although initially thought to hold
an advantage over IMRT primarily in pediatric and central
nervous system malignancies, multiple dosimetric studies
published in the past several years have demonstrated that
protons could prove to be superior in several other disease
sites as well, including prostate, gastrointestinal, and, most
pertinent to this review, thoracic malignancies. It is quite
possible that future studies will demonstrate that the theoret-
ical dosimetric advantages over photon techniques will ulti-
mately translate into clinical advantages as well, further
reducing toxicity in this patient subgroup receiving aggres-
sive treatment in a region surrounded by many sensitive and
vital structures.
*Department of Radiation Oncology, The University of Texas M. D. Ander-
son Cancer Center, Houston, Texas.
Disclosure: The authors declare no conflicts of interest.
Address for correspondence: Ritsuko Komaki, MD, epartment of Radia-
tion Oncology, The University of Texas M.D. Anderson Cancer
Center, Houston, Texas 77030. Email: rkomaki@mdanderson.org
Copyright © 2010 by the International Association for the Study of Lung
Cancer
ISSN: 1556-0864/10/0510-0336
Journal of Thoracic Oncology • Volume 5, Number 10, Supplement 4, October 2010S336
GENERAL PRINCIPLES OF RADIATION
THERAPY TECHNIQUES
Proper patient positioning and immobilization are es-
sential to the accurate delivery of radiation therapy in thy-
moma, regardless of technique. At M. D. Anderson Cancer
Center, patients are lied supine for simulation and are strictly
immobilized with a customized Vac-Loc cradle. The arms are
placed over the head and the hands gently grasp a T-bar.
Thin-cut computed tomography (CT) slices are then acquired
(2.5 mm), and intravenous contrast is used in select cases.
Next, a 4D CT scan is performed to assess for internal motion
and to be used for the purposes of treatment planning.
A complete review of the patient’s diagnostic imaging
studies is crucial to accurately delineate the target volume. It
is essential that preoperative imaging is available for review,
and that in the postoperative setting, the treatment volumes
are discussed with the surgeon. All questionable sites of
disease should be reviewed further with a diagnostic radiol-
ogist. Standard radiation treatment volumes include the gross
tumor volume (GTV) for gross disease, the clinical target
volume (CTV) for the GTV plus regions at risk for micro-
scopic spread, the internal target volume (ITV) to include the
CTV as well as internal motion, and the planning target
volume (PTV) to account for uncertainties in daily patient
positioning.6 In regard to the treatment volumes for thy-
moma, the region to be included in the CTV has varied by
study. Before the introduction of CT planning, the target
volume was often defined as the GTV, mediastinal lymph
nodes, and bilateral hilar lymph nodes,7 or the mediastinum
without the hilum. At our institution, we define the CTV as
the presurgical extent of disease, to include the entire surgical
bed, without elective nodal radiation. Acceptable radiation
doses for thymoma are as follows: 45 to 50 Gy in the
postoperative setting for negative margins, 54 Gy for positive
margins, and 60 to 70 Gy in the case of gross residual disease.
In general, 1.8 to 2.0 Gy fractions are used.
CONVENTIONAL (2D) RADIATION
TECHNIQUES FOR THYMOMA
Before the advent of conformal techniques, patients
were treated with two-dimensional methods in which one or
two radiation beams were directed at the target region and
were shaped using blocks placed at the head of the machine
(Figure 1). These blocks were often made of cerrobend, a
mixture of bismuth, lead, tin, and cadmium, and were formed
using a heating process until reaching the melting point of
158°F. There were many disadvantages to this technique. The
target was often identified solely by surface anatomic land-
marks or fluoroscopy, the small number of beams limited
the amount of conformality that could be achieved on 3D
structures, and doses were generally prescribed to a point
without corrections for variations in tissue density (most
notably lung density). Figure 2 demonstrates different
beam arrangements with this technique and the radiation
dose distributions that result.
There have been a wide variety of serious toxicities
reported with conventional techniques, with 5 to 15% rates of
grade 3 to 4 toxicities and 1 to 10% rates of grade 5 toxicities.
For example, Mornex et al.8 reported that 7 of 90 patients
experienced grade 3 or 4 toxicities after treatment with
surgery and postoperative radiation therapy, 3 patients with
pericarditis and 4 with lung fibrosis. Nakao et al.9 reported a
case of complete ventricular block after radiation therapy,
which was attributed to damage to the conduction system.
Uematsu et al. reported significant toxicity in 4 of 40 patients
receiving postoperative radiation after complete resection in
stage II to III thymoma. Three of four complications occurred
in patients receiving an extended field including the entire
hemithorax at 15 Gy in 15 fractions.10 Finally, Latz et al.11
reported multiple high-grade toxicities in the setting of sur-
gical resection and postoperative radiation with conventional
techniques: pulmonary embolism (grade 5), radiation pneu-
monitis (two cases, grades 3 and 4), and sternal fistula.
However, it should be noted that only two of these compli-
cations occurred after the completion of radiation therapy.
Although the radiation treatment field in thymoma is
almost always located adjacent to critical structures, high-
grade toxicity rates of 10 to 15% are considered unacceptable
given that long-term survival in this disease is high and that
patients are often otherwise relatively healthy. Therefore, the
focus on advances in radiation therapy over the past 10 to 15
years has been on increasing dose conformality and thus
increasing the therapeutic ratio. That is, the dose to the target
divided by the dose to normal tissue. These aims have been
largely achieved through the development of 3D conformal
radiation and, subsequently, IMRT.
FIGURE 1. Early two-dimensional thoracic radiotherapy.
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3D CONFORMAL RADIATION
Three-dimensional conformal radiation differs from
historical 2D techniques in that the planning is CT based on
“beam’s eye view” technology is used in which the beam is
shaped from multiple angles. Figure 3 demonstrates this
principle with a radiation treatment field typical of thymoma,
directly superior to the heart and surrounded by lung tissue.
Rather than cerrobend blocks, multileaf collimators are often
used to shape the beam, which are built into the head of the
gantry, as are shown in Figure 3C. In addition to increased
conformality, 3D conformal radiation allows for evaluation
of the treated doses as a function of dose and volume in a
representation known as a dose-volume histogram. Radiation
toxicity is directly correlated with the volume of tissue
receiving a given dose, and as can be seen in Figure 4, with
3D conformal planning, the beam arrangement can be opti-
mized such that the target volumes (GTV/CTV/PTV) receive
the prescription dose (70 Gy), whereas the normal structures
are constrained to lower doses.
INTENSITY-MODULATED RADIATION THERAPY
Although 3D conformal radiation offers a significant im-
provement over 2D techniques, IMRT offers yet another ad-
vance in terms of improving dose conformality and limiting the
dose to the surrounding critical structures of the heart, esopha-
gus, lung, and spinal cord. The physician and physicist involved
in planning the radiation are able to optimize the dose to the
tumor and normal tissues by using a “cost-benefit” algorithm in
which the planner specifies the priorities of treatment (tumor
coverage, heart dose, lung dose, etc.) and the treatment planning
system then designs an optimal plan based on these prespecified
priorities, a process termed “inverse planning.” The physician
and physicist then work to modify and fine-tune this plan
through techniques such as adding avoidance structures and
altering the cost-benefit ratios. IMRT also achieves a higher
level of conformality than 3D conformal treatment by using a
delivery system that modulates the intensity of each beam during
radiation delivery with dynamic multileaf collimators. The tech-
nique and indications of IMRT have been well described in
FIGURE 2. Isodose distributions with various beam arrangements in 2D treatment planning to a prescription dose of 5000
cGy. A, Single anterior to posterior (AP) beam with a significant hot spot anteriorly. B, Anterior and posterior beams (AP/PA)
beams weighted 2:1 anteriorly because of the anterior location of the tumor. It is evident that amount of tissue receiving a
dose 120% of the prescription level (6600 cGy) is greatly reduced, although the amount of conformality is limited. C,
Wedged pair technique using oblique beams, which improves conformality as compared with the former two techniques but
still contains large significant hot spots in the region of normal tissue.
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many publications, including recent consensus guidelines by the
American Society for Therapeutic Radiology and Oncology and
the American College of Radiology.12 Figure 5 depicts an
example of the differences in planning and treatment of an
intrathoracic tumor in an individual patient. It is evident that the
isodose lines extend to the surface both anteriorly and laterally in
the case of 3D conformal planning, whereas IMRT offers a more
conformal distribution. Figure 6 demonstrates IMRT in the
postoperative treatment of an invasive thymoma, with signifi-
cant sparing of the posterior structures and the heart.
Because of the rarity of invasive thymomas, the majority
of published studies are retrospective reviews spanning several
decades. As a result, there have been no dedicated studies
examining the toxicity of radiation in the setting of thymoma
with 3D conformal radiation or IMRT as compared with con-
ventional techniques. However, until the results of patients
treated with modern techniques mature, toxicity outcomes can
be extrapolated from those patients with other thoracic tumors,
such as lymphoma and non-small cell lung cancer (NSCLC).
Nieder et al. compared the dose distribution of three different
mediastinal radiotherapy techniques in female patients: 2D
AP/PA opposed fields, four-field 3D conformal techniques, and
a seven-field IMRT technique. Better heart sparing was achieved
with conformal techniques, particularly IMRT as compared with
the 2D technique. There was also a decrease in the maximum
dose to the breasts with IMRT.13 Komaki and coworkers com-
pared outcomes for patients with medically inoperable stage I
NSCLC treated with 2D versus 3D radiation and found that
overall survival, disease-free survival, and locoregional control
rates were superior with 3D conformal treatment.14 Wilson et
al.15 performed a dosimetric comparison with these same two
techniques in locally advanced NSCLC and found that spinal
cord and lung doses were significantly lower and tumor control
higher with 2D techniques. Finally, Liao et al. compared IMRT
with 3D conformal techniques with concomitant chemotherapy
for the treatment of NSCLC. The authors found that the toxicity
FIGURE 3. Beam’s eye view tech-
nology with computed tomogra-
phy-based 3D conformal planning.
A, The target region in pink (blue
arrow). Lungs  gold, heart  red,
esophagus  green. B, Shaping of
the tumor using multileaf collima-
tors located in the head of the ma-
chine as pictured in (C).
FIGURE 4. Dose-volume histogram to a tumor treated to a
prescription dose of 70 Gy. Maroon  GTV, gold  CTV,
aqua  PTV, green  esophagus, pink  heart, red  spinal
cord, orange  expanded spinal cord, blue  total lung.
While the tumor is receiving the prescription dose, the nor-
mal structures are all receiving doses below radiation toler-
ance. GTV, gross tumor volume; CTV, gross target volume;
PTV, planning target volume.
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rate was significantly lower in the IMRT group, and that the
rates of freedom from locoregional progression and distant
metastasis were at least as good with IMRT.16
4D TREATMENT PLANNING
In addition to using highly conformal techniques to target
thymic tumors and other thoracic malignancies, an advance in
technology that has further improved target localization and in
the process reduced the dose to normal structures is the devel-
opment of 4D treatment planning, i.e., quantitating tumor mo-
tion during treatment planning and accounting for this motion in
radiation delivery. Figure 7 demonstrates an example of how this
technique can be advantageous compared with treatment plans
that do not take into account tumor motion. In patients with a
great deal of tumor motion, the risk of marginal failures can be
substantially increased. It is notable that structures in the lower
portions of the thoracic cavity (closer to the diaphragm) tend to
have more respiratory variation than superior structures,17,18
such that the magnitude of internal motion for thymic tumors
would be expected to increase for treatment fields that have
significant inferior thoracic extension.
As noted above, the International Commission of Radia-
tion Units has expanded its definitions to include the ITV that is
defined as the CTV plus internal motion. There have been
several prior studies examining the feasibility and reproducibil-
ity of the addition of the ITV with 4D CT imaging in intratho-
racic tumors, primarily in the setting of NSCLC. Redmond et al.
examined 4D CT scans at simulation and from two rescans to
determine whether the excursion of tumors at simulation was
consistent at the time of rescanning. The authors concluded that
the addition of the ITV was useful as a target volume, and that
there was interfraction consistency in tumor excursion such that
motion assessment at the time of simulation could direct thera-
py.19 Liu et al. quantitated the degree of internal motion caused
by respiration in the setting of stage III or IV NSCLC. The
authors found that tumor motion was associated with diaphragm
motion, the superior-inferior location of the lung, the size of the
GTV (with smaller tumors moving more), and the disease
T-stage. Almost 40% of tumors moved0.5 cm in the superior-
inferior direction, whereas approximately 5% or less of tumors
moved 0.5 cm in the anterior-posterior or lateral directions.
Therefore, the authors concluded that only a small percentage of
patients would have internal motion 1.0 cm, and that the
largest excursion was in the superior-inferior direction.
At our institution, because expanding the tumor volume
by 1.0 cm or more could lead to significantly more normal
FIGURE 5. A patient with an in-
trathoracic tumor being treated
with (A) 3D conformal radiation and
(B) intensity-modulated radiation
therapy (IMRT). It is evident that
the plan is more conformal with
IMRT, with the isodose lines being
less extensive anteriorly and particu-
larly laterally.
FIGURE 6. Postoperative intensity-modulated radiation therapy (IMRT) for an invasive thymoma. The tumor is depicted in
(A) and the postoperative field in (B) and (C). IMRT offers a high level of dose conformality and sparing of the structures pos-
terior to the tumor bed in the anterior mediastinum.
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lung tissue receiving radiation (as the target volume would
move in and out of normal uninvolved lung parenchyma),
patients who exceed a threshold of 1.0 cm target volume
motion are treated with radiation coordinated breathing con-
trol. That is, the target volume is contoured at a given phase
of the respiratory cycle and treatment is delivered at that
cycle. Patients are coached during both radiation simulation
and the first treatment as to breathing patterns that will be the
most reproducible, and the respiratory cycle is monitored in
real-time with each fraction to ensure appropriate radiation
delivery. Multiple studies have demonstrated that planning
with radiation coordinated breathing control can decrease
doses to normal tissues while maintaining target doses. In one
such study, Vlachaki et al.20 found that with radiation coor-
dinated breathing control in 10 patients, the volume of lung
receiving doses of at least 20 Gy/10 Gy and above was
26%/31% for gated plans and 35%/40% for nongated plans.
In another study, George et al.21 found that the learning curve for
breath coaching was steep, and that the margins placed for
residual motion during treatment were consistent. Therefore,
although more time-consuming and requires more resources
than the alternative of delineating an ITV, in well-selected
patients, radiation coordinated breathing control is feasible and
can spare lung tissue in patients with significant tumor motion.
ADAPTIVE RADIATION THERAPY
In addition to accounting for internal motion during
treatment, current advances in technology have focused on
adapting for changes in anatomy and target volume as a result
of such factors as tumor response, inflammatory changes
related to treatment, breathing patterns, and alterations in
patient weight. Several investigators have examined the im-
pact of these changes during the course of radiation therapy.
Britton et al. obtained weekly 4D CT scans from 10 patients
with NSCLC to examine the effects of interfractional changes
on the doses to both the target volume and normal tissue.
While the mean change in dose to the PTV was only 12%, the
SD was 12%, implying that a meaningful percentage of
patients experienced significant variations in the target dose
distribution. In addition, while the mean lung dose and
percentage of lung receiving greater than 20 Gy (V20)
changed by an average of 5% during treatment, the maxi-
mum spinal cord dose changed by an average of 34%. The
authors concluded that because in a small percentage of
patients interfractional changes had “dramatic dosimetric
consequences,” repeat imaging should be considered during
treatment, particularly in locally advanced NSCLC patients.22
Spoelstra et al. examined the role of adaptive radiother-
apy from a prospective standpoint during concurrent chemo-
radiotherapy in 24 patients and assessed the benefit of routine
gating of all patients at a given time point. All patients
underwent gated radiation therapy delivery after 15 fractions,
and plan modification was initiated by either a 5% reduc-
tion in PTV coverage or an unacceptable increase in normal
tissue dose. The authors found that 15 patients had an average
reduction in PTV of 8% after 30 Gy, and that the PTV
increased in the remaining 6 patients. However, in only one
patient the increase was20%, and the patient was replanned
FIGURE 7. Comparison of target volumes without and with 4D treatment planning for a lung tumor. A, Conformal planning
without taking into account internal motion. It is evident that the tumor falls directly outside the treatment field with respira-
tory motion, which could then lead to a local failure as a result of underdosing the disease. B, Conformal 4D planning. When
respiratory motion is quantitated at radiation simulation, the treatment volume is expanded and the tumor remains well
within the radiation field.
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for progression of disease. As only one patient required
replanning, the conclusion of the study was that although
repeat imaging may provide utility in the setting of conformal
treatment methods for certain patients, daily gated radiother-
apy may reduce the need for adaptive planning.23 At our
institution, we routinely perform repeat 4D simulations at
approximately midway through treatment for patients with
intact thymoma due to the proximity of these tumors to
several critical structures, with more frequent adaptive sim-
ulations being done in patients with large-volume disease. A
decision regarding replanning is then made on discussion
among the treating physician, the planning dosimetrists, and
the physicist.
PROTON RADIATION
In the past decade, there has been a surge of proton
centers in the United States for treatment of a wide array of
malignancies, and many more treatment centers are planned.
Although no studies have been dedicated to thymomas, sev-
eral dosimetric investigations have established that for in-
trathoracic tumors, the favorable dose distribution of protons
in comparison with photons (in the form of the “Bragg Peak”)
can maintain a high conformal dose to the target tissue while
minimizing the dose to normal structures. Chang et al.24
published a study that compared normal tissue dose with
conformal techniques (3D conformal treatment or IMRT)
versus that with proton therapy in stage I or stage III NSCLC.
FIGURE 8. Patient with stage III invasive thymoma treated with proton therapy postoperatively. A and B, The preoperative
site of disease (blue arrow) with an adjacent pleural effusion. C, An axial view of the treatment plan. D, A sagittal view. It is
apparent that the dose volume is steep and that the stopping power of proton therapy allows for significant sparing of the
surrounding normal structures.
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With a detailed dosimetric analysis, the authors found that
doses to several organs, including the spinal cord, heart,
esophagus, and the integral radiation dose, were all lower
with proton therapy as compared with the photon techniques.
In another study, Chera et al. compared three different in-
volved nodal irradiation techniques for stage II Hodgkin
lymphoma patients: conventional radiation, IMRT, and 3D
proton radiotherapy. The authors found that proton therapy
significantly reduced the dose to the breast, lung, and total
body.25 Several prospective studies are currently underway
assessing whether these dosimetric advantages translate to
long-term clinical advantages in terms of local control, par-
ticularly toxicity.
At our institution, we strongly consider proton radiation
therapy in any patient being treated with invasive thymoma due
to the location of the disease in the anterior mediastinum, a
location in which the Bragg Peak could be effectively applied to
minimize dose to the underlying critical structures of the heart,
lung, and esophagus. Figure 8 demonstrates a patient with
invasive thymoma being treated with proton therapy in which it
is evident that the dose falloff to the underlying structures is
steep. Many institutions, including ours, are currently in the
process of applying the conformal advantages of IMRT with the
dose distribution superiority of proton therapy by implementing
intensity-modulated proton therapy.26 By combining intensity-
modulated proton therapy with the techniques of 4D CT imaging
and adaptive planning in invasive thymoma, the goal is to
provide a culmination of the technologic advantages over the
past decade to maximize the therapeutic ratio and thus to provide
long-term local control while maintaining a high quality of life
in this curable disease.
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